Armata Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
ARMP$3.80+8.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Number | Description | |
| 3.1 | | Amended and Restated Articles of Incorporation of the Company, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 16, 2015). |
| | | |
| 3.2 | | Articles of Amendment to Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K (File No. 001-37544), filed with the SEC on April 24), 2017. |
| | | |
| 3.3 | | Statement of Correction to Articles of Amendment to Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q, filed on November 8, 2018). |
| | | |
| 3.4 | | Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on December 18, 2018). |
| | | |
| 3.5 | | Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on May 10, 2019). |
| | | |
| 3.6 | | Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on December 11, 2019). |
| | | |
| 3.7 | | Articles of Amendment to Articles of Incorporation of the Company (effective March 26, 2020) (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 30, 2020). |
| | | |
| 3.8 | | Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.5 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019). |
| | | |
| 3.9 | | Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed with the SEC on December 11, 2019). |
| | | |
| 3.10 | | Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on February 26, 2020). |
| | | |
| 4.1 | | Reference is made to Exhibits 3.1 through 3.10. |
| | | |
| 10.1 | | Employment Letter Agreement by and between Mina Pastagia, M.D. and the Company, dated as of September 22, 2020 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on July 25, 2024). |
| | | |
| 10.2 | | Amendment No. 1, dated as of July 22, 2024, to that certain Employment Letter Agreement by and between Mina Pastagia, M.D. and the Company, dated as of September 22, 2020 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on July 25, 2024). |
| | | |
| 10.3 | | Employment Letter Agreement, dated July 31, 2024, by and between Armata Pharmaceuticals, Inc. and David House (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on August 15, 2024). |
| | | |
| 10.4 | | Confidential Separation and Release Agreement by and between Armata Pharmaceuticals, Inc. andRichard Rychlik dated as of September 30, 2024 (incorporated by reference to Exhibit 10.1 to theCompany’s Current Report on Form 8-K, filed with the SEC on October 3, 2024). |
| | | |
| 31.1 | | Certification of Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a). |
| | | |
| 31.2 | Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a). | |
| | | |
| 32.1† | Certification of Principal Executive Officer Required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350. | |
| | | |
| 32.2† | Certification of Principal Financial Officer Required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350. | |
| | | |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
| | | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | |
| | | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |
| | | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |
| | | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |
| | | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | |
| | | |
| 104 | | Cover Page Interactive Data File Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| † | The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.